Dutch Healthcare Authority advises to implement value-based funding of medical specialist care

20

Nov 2018

Value-based contracting must become the norm so that care in the right place and efficient use of people and resources comes a step closer. New model of funding is necessary in order to keep the healthcare affordable in the long-term perspective. This is stated in the Advice on the financing of medical specialist care “Rewards of care that adds value” to the Minister of Health.

Dutch Healthcare Authority (NZa) have agreed with care providers and health insurers that they take health gains for patients as the starting point in the contracts. The incentives for this value-driven care are laid down in contracts whereby agreements are made about quality and outcomes. In these agreements, patient demand is central and is paid for in bundles of existing healthcare products. This gives the patient the right care in the right place. Transparency about the outcomes of healthcare is a precondition for this.

The DRG system has a different, less meaningful role. The medical specialist care is recorded and declared with diagnosis treatment combinations (DRG). These DRGs will continue to exist in the coming years and will be changed as little as possible. Innovative agreements in contracts benefit from a stable declaration system. DRG healthcare products become less significant in the financial agreements between care providers and health insurers.

See full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

25

Mar 2022

On March 4, 2022, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced three projects which received a subsidy under the "Subsidy scheme for promising care" in 2022 for research of a new minimally invasive endoscopy-guided surgery in patients with spontaneous cerebral hemorrhage, oral immunotherapy in children to cure a food allergy and cutting the diaphragm band in chronic abdominal complaints.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more

07

Mar 2022

On February 08, 2022, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique. The main changes relate to the increase in reimbursement fees of services and medical devices by approximately 35-75%.

Read more